From: guy.as.wingate@gsk.com
Sent: Friday, July 09, 2004 4:48 AM
To: fdadockets@oc.fda.gov
Subject: GSK Comments for Docket No. 2004N-0133

Please find attached pdf from GlaxoSmithKline in response to FDA request for public comments concerning potential Part 11 rulemaking. 
Thank you for your consideration.  Paper copy sent by Courier. 



Kind regards,

Dr Guy Wingate
Director - Global Computer Validation
Global Manufacturing & Supply
GlaxoSmithKline